Asie N. Useinova
Research Subjects
Asie N. Useinova has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Egorova
Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. Vernadsky
8 shared publications - Sofiya P. Maryanenko
Order of the Red Banner of Labour S.I. Georgievsky Medical Institute of the V.I. Vernadsky Crimean Federal University
7 shared publications - Ksenia N. Koryanova
Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University. 2. Russian Medical Academy of Continuing Professional Education
4 shared publications - Vitalii B. Kaliberdenko
V.I. Vernadsky Crimean Federal University Department of internal medicine no. 2 Simferopol Ukraine
4 shared publications - A. M. Beitullaev
Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. Vernadsky
2 shared publications - D. V. Solomko2 shared publications
Latest Publications
- 11 November 2025
- Published by Media Sphere Publishing Group in Problems of Balneology, Physiotherapy and Exercise Therapy
- Vol. 102 (5) , 48-55
Modern methods of rehabilitation of patients with different degrees of multiple sclerosis. (Literature review)
Multiple sclerosis is a chronic autoimmune disease that causes damage to the myelin sheath of the nerve fibers, which leads to various neurological symptoms. Over the past 30 years, a significant advance in studying the pathogenesis of multiple sclerosis has been achieved and progress in symptomatic treatment of the disease, including control of secondary manifestations, has been noted. Rehabilitation plays an important role in the management of this disease. Physical rehabilitation, which includes physiotherapy and therapeutic exercise, is the main part of rehabilitation. Psychological rehabilitation, which includes psychotherapy and stress management techniques, is another important part of rehabilitation. The article considers modern methods of rehabilitation of patients with multiple sclerosis aimed at improving the quality of life of patients and minimizing the consequences of the disease.
- 11 November 2025
- Published by Media Sphere Publishing Group in Problems of Balneology, Physiotherapy and Exercise Therapy
- Vol. 102 (5) , 48-55
Modern methods of rehabilitation of patients with different degrees of multiple sclerosis. (Literature review)
Multiple sclerosis is a chronic autoimmune disease that causes damage to the myelin sheath of the nerve fibers, which leads to various neurological symptoms. Over the past 30 years, a significant advance in studying the pathogenesis of multiple sclerosis has been achieved and progress in symptomatic treatment of the disease, including control of secondary manifestations, has been noted. Rehabilitation plays an important role in the management of this disease. Physical rehabilitation, which includes physiotherapy and therapeutic exercise, is the main part of rehabilitation. Psychological rehabilitation, which includes psychotherapy and stress management techniques, is another important part of rehabilitation. The article considers modern methods of rehabilitation of patients with multiple sclerosis aimed at improving the quality of life of patients and minimizing the consequences of the disease.
- 2 July 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (2) , 173-179
Epidemiological Characteristics of Multiple Myeloma in the Republic of Crimea
INTRODUCTION: The epidemiology of multiple myeloma (MM) in Russia has not been sufficiently studied, however, it is important for understanding its prevalence in connection with increase in life expectancy of the population and the projected increase in morbidity MM. AIM: To study the main epidemiological and clinical-demographic indicators of MM in the Republic of Crimea for 2019–2022. MATERIALS AND METHODS: A prospective analysis of medical records of 173 patients with MM, who were undergoing outpatient and inpatient treatment in the hematology and chemotherapy department of Efetov Crimean Republican Oncological Clinical Dispensary was conducted. Statistical analysis of the data was conducted using the Microsoft Office application package and descriptive and parametric statistical methods. RESULTS: Of the 713 patients MM were diagnosed of 91 women (66.5±11.1) years and 82 men (59.7±10.0) years. The men-to-women ratio was 0.9:1, which does not correspond to the global trends in MM development. The average incidence during the study period was 1.4 per 100 thousand, the average prevalence was 3.92 per 100 thousand, with the prevalence rate increased by 67.0% from the baseline. Patients with stage III of the disease according to the Durie–Salmon classification predominated — 97 (56.0%) patients. Mortality was 8.5 per 100 thousand among men and 6.0 per 100 thousand among women. The 5-year survival rate of patents with MM was 45.0%, the median survival was 38 months. CONCLUSION: The prevalence of MM in the Republic of Crimea almost twice exceeds that in other regions of Russia. A steady increase in the incidence rate has been detected, which is probably due to improvement of the MM detectability as a result of regular prophylactic medical examinations of the population.
- 2 July 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (2) , 173-179
Epidemiological Characteristics of Multiple Myeloma in the Republic of Crimea
INTRODUCTION: The epidemiology of multiple myeloma (MM) in Russia has not been sufficiently studied, however, it is important for understanding its prevalence in connection with increase in life expectancy of the population and the projected increase in morbidity MM. AIM: To study the main epidemiological and clinical-demographic indicators of MM in the Republic of Crimea for 2019–2022. MATERIALS AND METHODS: A prospective analysis of medical records of 173 patients with MM, who were undergoing outpatient and inpatient treatment in the hematology and chemotherapy department of Efetov Crimean Republican Oncological Clinical Dispensary was conducted. Statistical analysis of the data was conducted using the Microsoft Office application package and descriptive and parametric statistical methods. RESULTS: Of the 713 patients MM were diagnosed of 91 women (66.5±11.1) years and 82 men (59.7±10.0) years. The men-to-women ratio was 0.9:1, which does not correspond to the global trends in MM development. The average incidence during the study period was 1.4 per 100 thousand, the average prevalence was 3.92 per 100 thousand, with the prevalence rate increased by 67.0% from the baseline. Patients with stage III of the disease according to the Durie–Salmon classification predominated — 97 (56.0%) patients. Mortality was 8.5 per 100 thousand among men and 6.0 per 100 thousand among women. The 5-year survival rate of patents with MM was 45.0%, the median survival was 38 months. CONCLUSION: The prevalence of MM in the Republic of Crimea almost twice exceeds that in other regions of Russia. A steady increase in the incidence rate has been detected, which is probably due to improvement of the MM detectability as a result of regular prophylactic medical examinations of the population.
- 28 May 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 6,p. 764-771
A fundamentally new possibility of pharmacotherapy for postpartum depression
The article discusses new therapeutic options for the treatment of postpartum depression using zuranolone. The authors' independent literature review includes an analysis of the clinical trials "MOUNTAIN-A", "3 CORAL" and "SAGE-217". The generalizations made in the course of the work emphasize the innovative mechanism of action of zuranolone as a positive allosteric modulator of GABAa receptors, its ability to quickly relieve symptoms of depression, and its potential value in the context of personalized therapy. The introduction of zuranolone into the treatment of postpartum depression may be promising, given that it is the first oral drug of this group available for its treatment.
- 28 May 2025
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 6,p. 764-771
A fundamentally new possibility of pharmacotherapy for postpartum depression
The article discusses new therapeutic options for the treatment of postpartum depression using zuranolone. The authors' independent literature review includes an analysis of the clinical trials "MOUNTAIN-A", "3 CORAL" and "SAGE-217". The generalizations made in the course of the work emphasize the innovative mechanism of action of zuranolone as a positive allosteric modulator of GABAa receptors, its ability to quickly relieve symptoms of depression, and its potential value in the context of personalized therapy. The introduction of zuranolone into the treatment of postpartum depression may be promising, given that it is the first oral drug of this group available for its treatment.
- Open Access
- 13 February 2025
- Published by Baltic Medical Education Center in HIV Infection and Immunosuppressive Disorders
- Vol. 16 (4) , 66-72
Аnalysis of cases of adverse reactions during the use of antiretroviral therapy in pregnant women
Antiretroviral therapy is a treatment that involves the regular use of a combination of antiviral drugs. During pregnancy, women with human immunodeficiency virus (HIV) do not stop antiretroviral treatment, as this is necessary to reduce the risk of HIV transmission from the mother to the fetus. However, the body of a pregnant woman can affect the way the antiretroviral medications work, called their pharmacokinetics and pharmacodynamics. This can increase the risk of adverse drug reactions (ADR) from the medications.The aim of the study was investigated of the frequency of ADR of antiretroviral therapies based on analysis of spontaneous reports of ADR among pregnant women who were registered in the ARCADe regional database (Adverse Reactions in Crimea, Autonomous Database). Materials and methods. The study included 64 spontaneous ADR reports registered in the electronic database of spontaneous ARCADE messages in the Republic of Crimea between January 1, 2012 and December 31, 2021. These reports were collected from pregnant women who were taking ARP.Results and discussion. The most common types of ADR have been reported when using combined antiretroviral medications and nucleoside reverse transcriptase inhibitor drugs. The combination of lamivudine and zidovudine drugs was the most frequent cause of adverse effects among pregnant women on antiretroviral therapy. Hematopoietic disorders and dyspepsia were the most prevalent clinical manifestations of the ADR. Almost 85% of identified ADR required medication adjustment, although only 5% were classified as severe manifestations of the events.Conclusion. Long-term antiretroviral drug use requires regular monitoring of ADR, particularly during pregnancy, to provide timely care and maintain high levels of patient adherence to an effective antiretroviral treatment regimen. Despite the high incidence of anemia, skin, and dyspeptic problems, the proportion of serious ADR was found to be relatively low, which justifies the use of antiretroviral therapy during pregnancy. This justifies the continued use of antiretroviral therapy during pregnancy, as it has undeniable benefits in preventing transmission of HIV from mother to child, suppressing viral replication, and reducing mortality in infants.
- 13 February 2025
- Published by Baltic Medical Education Center in HIV Infection and Immunosuppressive Disorders
- Vol. 16 (4) , 66-72
Open AccessАnalysis of cases of adverse reactions during the use of antiretroviral therapy in pregnant women
Antiretroviral therapy is a treatment that involves the regular use of a combination of antiviral drugs. During pregnancy, women with human immunodeficiency virus (HIV) do not stop antiretroviral treatment, as this is necessary to reduce the risk of HIV transmission from the mother to the fetus. However, the body of a pregnant woman can affect the way the antiretroviral medications work, called their pharmacokinetics and pharmacodynamics. This can increase the risk of adverse drug reactions (ADR) from the medications.The aim of the study was investigated of the frequency of ADR of antiretroviral therapies based on analysis of spontaneous reports of ADR among pregnant women who were registered in the ARCADe regional database (Adverse Reactions in Crimea, Autonomous Database). Materials and methods. The study included 64 spontaneous ADR reports registered in the electronic database of spontaneous ARCADE messages in the Republic of Crimea between January 1, 2012 and December 31, 2021. These reports were collected from pregnant women who were taking ARP.Results and discussion. The most common types of ADR have been reported when using combined antiretroviral medications and nucleoside reverse transcriptase inhibitor drugs. The combination of lamivudine and zidovudine drugs was the most frequent cause of adverse effects among pregnant women on antiretroviral therapy. Hematopoietic disorders and dyspepsia were the most prevalent clinical manifestations of the ADR. Almost 85% of identified ADR required medication adjustment, although only 5% were classified as severe manifestations of the events.Conclusion. Long-term antiretroviral drug use requires regular monitoring of ADR, particularly during pregnancy, to provide timely care and maintain high levels of patient adherence to an effective antiretroviral treatment regimen. Despite the high incidence of anemia, skin, and dyspeptic problems, the proportion of serious ADR was found to be relatively low, which justifies the use of antiretroviral therapy during pregnancy. This justifies the continued use of antiretroviral therapy during pregnancy, as it has undeniable benefits in preventing transmission of HIV from mother to child, suppressing viral replication, and reducing mortality in infants.
- 1 January 2025
- Published by Scientific and Practical Center "Psychea" in Psychiatry and psychopharmacotherapy
- Vol. 27 (1)
Zuranolone: a new approach to pharmacotherapy of postpartum depression
Postpartum depression poses a serious threat to the mental health and well-being of the mother, and also negatively affects the mother's relationship with her child, leading to serious consequences that can hinder the growth and cognitive development of the child. For decades, antidepressants have been the mainstay of treatment for postpartum depression, but recent evidence suggests that traditional antidepressants are not as effective as they are thought to be, and there is an urgent need to explore new pharmacotherapy options. In 2023, there was a breakthrough in its treatment when the FDA approved zuranolone, a selective positive allosteric modulator of the gamma-aminobutyric acid receptor. The purpose of our review is to discuss the latest clinical trials that have been conducted to confirm the effectiveness of zuranolone in alleviating the symptoms of postpartum depression, which leads to an improvement in the quality of life of mothers. The research has been selected over the past 4 years in such electronic information resources as the Elsevier Library, PubMed, NCBI, Google Scholar, eLibrary. All of them confirmed its effectiveness in alleviating the symptoms of postpartum depression. The introduction of zuranolone into her treatment may prove revolutionary, given that it is the first oral drug available for her treatment.
- 1 January 2025
- Published by Scientific and Practical Center "Psychea" in Psychiatry and psychopharmacotherapy
- Vol. 27 (1)
Zuranolone: a new approach to pharmacotherapy of postpartum depression
Postpartum depression poses a serious threat to the mental health and well-being of the mother, and also negatively affects the mother's relationship with her child, leading to serious consequences that can hinder the growth and cognitive development of the child. For decades, antidepressants have been the mainstay of treatment for postpartum depression, but recent evidence suggests that traditional antidepressants are not as effective as they are thought to be, and there is an urgent need to explore new pharmacotherapy options. In 2023, there was a breakthrough in its treatment when the FDA approved zuranolone, a selective positive allosteric modulator of the gamma-aminobutyric acid receptor. The purpose of our review is to discuss the latest clinical trials that have been conducted to confirm the effectiveness of zuranolone in alleviating the symptoms of postpartum depression, which leads to an improvement in the quality of life of mothers. The research has been selected over the past 4 years in such electronic information resources as the Elsevier Library, PubMed, NCBI, Google Scholar, eLibrary. All of them confirmed its effectiveness in alleviating the symptoms of postpartum depression. The introduction of zuranolone into her treatment may prove revolutionary, given that it is the first oral drug available for her treatment.
- 27 July 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 7,p. 883-895
Current practice in pharmacological treatment of generalized anxiety disorder
Generalized anxiety disorder is a common mental illness characterized by generalized anxiety and excessive worrying. Current therapy consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatment, and new anxiolytic drugs are being developed. This review examines effective pharmacological treatments for generalized anxiety disorder and their tolerability. Finally, information on new anxiolytics under development is presented, with an emphasis on those that have completed clinical trials. A wide range of effective treatments for generalized anxiety disorder are available, with duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine being particularly commonly used. There is a limited evidence base for the pharmacological management of patients with generalized anxiety disorder who have not responded to initial treatment. Although many new anxiolytics have advanced to clinical trials, transition from animal models has been largely unsuccessful. However, the potential of several compounds, including psilocybin, ketamine, oxytocin, and orexin- and endocannabinoid-modulating compounds, merit further study.
- 27 July 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 7,p. 883-895
Current practice in pharmacological treatment of generalized anxiety disorder
Generalized anxiety disorder is a common mental illness characterized by generalized anxiety and excessive worrying. Current therapy consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatment, and new anxiolytic drugs are being developed. This review examines effective pharmacological treatments for generalized anxiety disorder and their tolerability. Finally, information on new anxiolytics under development is presented, with an emphasis on those that have completed clinical trials. A wide range of effective treatments for generalized anxiety disorder are available, with duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine being particularly commonly used. There is a limited evidence base for the pharmacological management of patients with generalized anxiety disorder who have not responded to initial treatment. Although many new anxiolytics have advanced to clinical trials, transition from animal models has been largely unsuccessful. However, the potential of several compounds, including psilocybin, ketamine, oxytocin, and orexin- and endocannabinoid-modulating compounds, merit further study.
- Open Access
- 7 July 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (3) , 159-167
A review of endocrine therapy for hormone-dependent breast cancer
Purpose of the study: to provide current data on pharmacotherapy of hormone-dependent breast cancer (hdBC) and to consider the feasibility of introducing new hormone therapy drugs for breast cancer into clinical practice. Material and Methods. We analyzed 80 publications available Pubmed, Springer, Cochrane Library, etc. concerning the study of pharmacological characteristics of various groups of drugs for the treatment of hdBC, of which 49 were included in this review. Results. Currently, there are several approaches to the treatment of hdBC. Selective estrogen receptor modulators and aromatase inhibitors are the most studied and frequently used drugs. The cyclin-dependent kinase 4/6 inhibitors can be present in both the first- and second-line therapy. Currently, close attention is paid to the development of new drugs based on genomic profiling of the tumor, which is the standard of treatment for hdBC, and contributes to the personalization of therapy. Conclusion. Further development of drugs holds great promise for increasing overall survival and more accurate prognosis, response to conventional systemic therapy, and individualization of pharmacotherapy for hdBC. However, further research and development of new drugs is required. In this regard, the introduction of oral selective estrogen receptor degraders into practice and the development of new drugs that block estrogen-dependent and independent signaling to estrogen receptors are the most promising trends.
- 7 July 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (3) , 159-167
Open AccessA review of endocrine therapy for hormone-dependent breast cancer
Purpose of the study: to provide current data on pharmacotherapy of hormone-dependent breast cancer (hdBC) and to consider the feasibility of introducing new hormone therapy drugs for breast cancer into clinical practice. Material and Methods. We analyzed 80 publications available Pubmed, Springer, Cochrane Library, etc. concerning the study of pharmacological characteristics of various groups of drugs for the treatment of hdBC, of which 49 were included in this review. Results. Currently, there are several approaches to the treatment of hdBC. Selective estrogen receptor modulators and aromatase inhibitors are the most studied and frequently used drugs. The cyclin-dependent kinase 4/6 inhibitors can be present in both the first- and second-line therapy. Currently, close attention is paid to the development of new drugs based on genomic profiling of the tumor, which is the standard of treatment for hdBC, and contributes to the personalization of therapy. Conclusion. Further development of drugs holds great promise for increasing overall survival and more accurate prognosis, response to conventional systemic therapy, and individualization of pharmacotherapy for hdBC. However, further research and development of new drugs is required. In this regard, the introduction of oral selective estrogen receptor degraders into practice and the development of new drugs that block estrogen-dependent and independent signaling to estrogen receptors are the most promising trends.
- 30 June 2024
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 3,p. 49-56
Prospects for using N-acetylcysteine in the treatment of obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) primarily has its clinical manifestations due to dysfunction in the glutamatergic system and modulation of inflammatory cytokines. Dysregulation of the glutamatergic system, the primary excitatory neurotransmitter system in the human brain, is directly related to the pathophysiology of OCD. Indeed, this system is critical for neuroplasticity, learning and memory, and recent studies have identified glutamatergic abnormalities in people with OCD. The worldwide prevalence of OCD is estimated at 2-3%, and this figure may be underestimated due to frequent misdiagnosis. Current first-line treatments include selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT). However, a significant proportion of patients remain refractory to these treatments, necessitating the search for alternative therapeutic strategies. This article examines the potential use of N-acetylcysteine (NAC) as an alternative treatment for obsessive-compulsive disorder.
- 30 June 2024
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 3,p. 49-56
Prospects for using N-acetylcysteine in the treatment of obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) primarily has its clinical manifestations due to dysfunction in the glutamatergic system and modulation of inflammatory cytokines. Dysregulation of the glutamatergic system, the primary excitatory neurotransmitter system in the human brain, is directly related to the pathophysiology of OCD. Indeed, this system is critical for neuroplasticity, learning and memory, and recent studies have identified glutamatergic abnormalities in people with OCD. The worldwide prevalence of OCD is estimated at 2-3%, and this figure may be underestimated due to frequent misdiagnosis. Current first-line treatments include selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT). However, a significant proportion of patients remain refractory to these treatments, necessitating the search for alternative therapeutic strategies. This article examines the potential use of N-acetylcysteine (NAC) as an alternative treatment for obsessive-compulsive disorder.
- Open Access
- 26 February 2024
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 68 (1) , 32-38
Pharmaceutical examination of prescriptions from pharmacy chains of the Republic of Crimea from 2020 to 2021
Introduction. Along with the correct diagnosis of the disease, the stage of choosing the means of pharmacological correction is important, as well as the correct registration of the application to the pharmacy and ensuring the patient’s access to the necessary medication. The purpose of the study is the pharmacological examination of prescription forms received by pharmacy institutions of the Republic of Crimea for the period 2020–2021. Materials and methods. The object of the study was a random sample of three hundred thirty two scanned copies of prescription forms No. 148-1/u-04 (L), No. 107-1/u. Additionally, we conducted a survey of pharmacy staff (n = 46). The questionnaire included questions on the analyzed error groups, and also assumed a subjective assessment of the impact of the fact of incorrect prescriptions on the work process. Over the course of the study, methods of analysis, descriptive statistics, comparison, and survey were used. Results. The main violations identified in the analyzed prescription forms were incorrect indications of the dosage forms (DF) of the prescribed drugs, as well as inaccuracies in their single and/or daily dosages. In 74 of the received recipes, errors were made when specifying the DF. The study of the frequency of prescribing medication of the certain pharmacological groups allowed determining the largest number of prescriptions to be written for drugs of the anxiolytic group, nootropic drugs, antidepressants. The result of a survey of employees of pharmacy chains revealed to be faced with incorrectly issued prescription forms on a daily basis. Limitations. During the pharmaceutical examination of copies of prescription forms received from pharmacy chains of the Republic of Crimea, 322 prescription forms were analyzed, which is a sufficient reference sample. Conclusion. When studying individual prescription forms, a sufficient number of various errors were revealed, which may entail a decrease in the quality of medical care for patients on the one hand, and on the other hand, suggests the occurrence of certain difficulties in the work of pharmaceutical workers.
- 26 February 2024
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 68 (1) , 32-38
Open AccessPharmaceutical examination of prescriptions from pharmacy chains of the Republic of Crimea from 2020 to 2021
Introduction. Along with the correct diagnosis of the disease, the stage of choosing the means of pharmacological correction is important, as well as the correct registration of the application to the pharmacy and ensuring the patient’s access to the necessary medication. The purpose of the study is the pharmacological examination of prescription forms received by pharmacy institutions of the Republic of Crimea for the period 2020–2021. Materials and methods. The object of the study was a random sample of three hundred thirty two scanned copies of prescription forms No. 148-1/u-04 (L), No. 107-1/u. Additionally, we conducted a survey of pharmacy staff (n = 46). The questionnaire included questions on the analyzed error groups, and also assumed a subjective assessment of the impact of the fact of incorrect prescriptions on the work process. Over the course of the study, methods of analysis, descriptive statistics, comparison, and survey were used. Results. The main violations identified in the analyzed prescription forms were incorrect indications of the dosage forms (DF) of the prescribed drugs, as well as inaccuracies in their single and/or daily dosages. In 74 of the received recipes, errors were made when specifying the DF. The study of the frequency of prescribing medication of the certain pharmacological groups allowed determining the largest number of prescriptions to be written for drugs of the anxiolytic group, nootropic drugs, antidepressants. The result of a survey of employees of pharmacy chains revealed to be faced with incorrectly issued prescription forms on a daily basis. Limitations. During the pharmaceutical examination of copies of prescription forms received from pharmacy chains of the Republic of Crimea, 322 prescription forms were analyzed, which is a sufficient reference sample. Conclusion. When studying individual prescription forms, a sufficient number of various errors were revealed, which may entail a decrease in the quality of medical care for patients on the one hand, and on the other hand, suggests the occurrence of certain difficulties in the work of pharmaceutical workers.
- Open Access
- 11 January 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 27 (6) , 275-284
Opportunities and prospects for the treatment of hormone-dependent breast cancer
The high incidence of breast cancer requires increased attention to the problem of rational pharmacotherapy of this condition. When choosing tactics for the treatment of breast cancer, it is recommended to take into account the immunohistochemical subtype of cancer cells. In the case of detection of estrogen-positive expression, an obligatory component of pharmacotherapy is endocrine therapy with antiestrogen orientation. Despite the fact that there are already many years of positive experience with the use of selective estrogen receptor modulators and aromatase inhibitors, the search for new more effective agents continues in terms of prolonging the life of patients and reducing the risk of adverse reactions. In recent years, cyclin-dependent kinase 4/6 inhibitors have been added to first-line therapy, which is a breakthrough in the treatment of metastatic breast cancer. The introduction of combined antiestrogen therapy with targeted agents that have the ability to inhibit phosphatidylinositol-3-kinase is logical in the event of resistance to primary endocrine therapy. However, the need to search and study new drugs remains. In this regard, the most promising direction is the development of agents that can reduce the expression of the Estrogen receptor alpha protein, and block estrogen-dependent and independent estrogen receptor signaling.
- 11 January 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 27 (6) , 275-284
Open AccessOpportunities and prospects for the treatment of hormone-dependent breast cancer
The high incidence of breast cancer requires increased attention to the problem of rational pharmacotherapy of this condition. When choosing tactics for the treatment of breast cancer, it is recommended to take into account the immunohistochemical subtype of cancer cells. In the case of detection of estrogen-positive expression, an obligatory component of pharmacotherapy is endocrine therapy with antiestrogen orientation. Despite the fact that there are already many years of positive experience with the use of selective estrogen receptor modulators and aromatase inhibitors, the search for new more effective agents continues in terms of prolonging the life of patients and reducing the risk of adverse reactions. In recent years, cyclin-dependent kinase 4/6 inhibitors have been added to first-line therapy, which is a breakthrough in the treatment of metastatic breast cancer. The introduction of combined antiestrogen therapy with targeted agents that have the ability to inhibit phosphatidylinositol-3-kinase is logical in the event of resistance to primary endocrine therapy. However, the need to search and study new drugs remains. In this regard, the most promising direction is the development of agents that can reduce the expression of the Estrogen receptor alpha protein, and block estrogen-dependent and independent estrogen receptor signaling.